SBIR/STTR Research Award

A New PET Labeled Maltodextrin for Diagnosis of Bacterial Infections

Award identifier 6b7a9a7fd1d575240742cd0df502ba7cee4f1cb7dd97d9b4a2c18d0afde8b470Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2016

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Microbial Medical, Inc.
Proposal award date
2016-07-01
Contract end date
2017-12-31
UEI
S2BNW6NL62E7
Solicitation number
PA15-269
Topic code
NIBIB

Research abstract

DESCRIPTION provided by applicant We present a new family of contrast agents based on targeting the maltodextrin transporter termed maltodextrin based imaging probes MDPs which are designed to image infections associated with implanted medical devices by fluorescent imaging The chemical structure of an MDP is composed of maltodextrins conjugated to the positron emitting radioelement fluorine MDPs have the potential to offer significant advantages over existing methods for imaging bacteria such as FDG as a result of their high specificity and sensitivity for bacteria MDPs target the maltodextrin transport pathway and are internalized as a major source of glucose by bacteria MDPs can therefore deliver millimolar concentrations of imaging probes into bacteria making it possible to image low numbers of bacteria MDPs also have high specificity for bacteria because mammalian cells do not express the maltodextrin transporter and thus cannot internalize contrast agents conjugated to maltose Finally MDPs are composed of glucose oligomers which are hydrophilic and membrane impermeable MDPs are therefore efficiently cleared from un infected tissues in vivo leading to low background in organs such as the heart and muscle which should lead to high sensitivity imaging of implanted device infections These unique properties allow MDPs to accurately image small numbers of bacteria in vivo MDPs thus have the unique properties allow MDPs to accurately image small numbers of bacteria in vivo MDPs thus have the potential to detect implant device infections at an early stage and enable their treatment before they are challenging to eradicate PUBLIC HEALTH RELEVANCE We present a new family of contrast agents based on targeting the maltodextrin transporter termed maltodextrin based imaging probes MDPs which are designed to image infections associated with implanted medical devices by fluorescent imaging The chemical structure of an MDP is composed of maltodextrins conjugated to the positron emitting radioelement fluorine MDPs have the potential to offer significant advantages over existing methods for imaging bacteria such as FDG as a result of their high specificity and sensitivity for bacteria MDPs target the maltodextrin transport pathway and are internalized as a major source of glucose by bacteria MDPs can therefore deliver millimolar concentrations of imaging probes into bacteria making it possible to image low numbers of bacteria MDPs also have high specificity for bacteria because mammalian cells do not express the maltodextrin transporter and thus cannot internalize contrast agents conjugated to maltose Finally MDPs are composed of glucose oligomers which are hydrophilic and membrane impermeable MDPs are therefore efficiently cleared from un infected tissues in vivo leading to low background in organs such as the heart and muscle which should lead to high sensitivity imaging of implanted device infections These unique properties allow MDPs to accurately image small numbers of bacteria in vivo MDPs thus have the unique properties allow MDPs to accurately image small numbers of bacteria in vivo MDPs thus have the potential to detect implant device infections at an early stage and enable their treatment before they are challenging to eradicate

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

4 SBIR/STTR records share this UEI (2015–2022). Reported award amounts total $1,936,677. Reported amounts are not federal obligations.

Phases: Phase I, Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.